Basilea Pharmaceutica AG Share Price Xetra
Stocks
PK5
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 80Cr 100Cr 86Cr 73Cr 137.65Cr 9.56TCr 139.46Cr 946.64Cr 369.16Cr 4.8TCr 375.37Cr 367.2Cr 16TCr | P/E 2026 * |
19x | P/E 2027 * | 19.5x |
|---|---|---|---|---|---|
| Enterprise Value | 65Cr 81Cr 70Cr 60Cr 111.86Cr 7.77TCr 113.34Cr 769.33Cr 300.01Cr 3.9TCr 305.06Cr 298.42Cr 13TCr | EV / Sales 2026 * |
2.5x | EV / Sales 2027 * | 2.17x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 100Cr | |
| +1.09% | +5.26% | +4.44% | +26.03% | 5.16TCr | |
| -1.07% | +2.82% | +474.18% | +601.24% | 4.49TCr | |
| +1.47% | +9.79% | +40.15% | +21.21% | 4.28TCr | |
| +1.44% | +7.77% | +19.27% | +90.94% | 4.26TCr | |
| -0.93% | -4.33% | +17.87% | +51.96% | 3.18TCr | |
| +1.32% | +7.30% | +36.93% | +152.36% | 1.73TCr | |
| -0.60% | +1.93% | - | - | 1.66TCr | |
| +0.03% | +3.41% | +7.12% | +35.49% | 1.48TCr | |
| +1.28% | +5.41% | +91.01% | +46.93% | 1.41TCr | |
| Average | +0.40% | +4.43% | +86.37% | +128.27% | 3.07TCr | |
| Weighted average by Cap. | +0.48% | +4.72% | +102.57% | +148.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 26Cr 33Cr 28Cr 24Cr 45Cr 3.11TCr 45Cr 307.94Cr 120.09Cr 1.56TCr 122.11Cr 119.45Cr 5.17TCr | 27Cr 34Cr 29Cr 25Cr 46Cr 3.23TCr 47Cr 319.61Cr 124.64Cr 1.62TCr 126.73Cr 123.98Cr 5.37TCr |
| Net income | 5.36Cr 6.68Cr 5.72Cr 4.9Cr 9.2Cr 639.34Cr 9.32Cr 63Cr 25Cr 321.17Cr 25Cr 25Cr 1.06TCr | 4.44Cr 5.54Cr 4.75Cr 4.07Cr 7.63Cr 530.39Cr 7.73Cr 52Cr 20Cr 266.44Cr 21Cr 20Cr 881.27Cr |
| Net Debt | -15Cr -19Cr -16Cr -14Cr -26Cr -1.79TCr -26Cr -177.31Cr -69Cr -899.96Cr -70Cr -69Cr -2.98TCr | -21Cr -27Cr -23Cr -20Cr -37Cr -2.55TCr -37Cr -252.47Cr -98Cr -1.28TCr -100.11Cr -98Cr -4.24TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
